STRUCTURE THERAPEUTICS INC (GPCR) Stock Price & Overview
NASDAQ:GPCR • US86366E1064
Current stock price
The current stock price of GPCR is 47.02 USD. Today GPCR is up by 1.12%. In the past month the price decreased by -2.31%. In the past year, price increased by 98.06%.
GPCR Key Statistics
- Market Cap
- 3.321B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.22
- Dividend Yield
- N/A
GPCR Stock Performance
GPCR Stock Chart
GPCR Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to GPCR. When comparing the yearly performance of all stocks, GPCR is one of the better performing stocks in the market, outperforming 80.47% of all stocks.
GPCR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GPCR. While GPCR has a great health rating, there are worries on its profitability.
GPCR Earnings
GPCR Forecast & Estimates
23 analysts have analysed GPCR and the average price target is 111.47 USD. This implies a price increase of 137.07% is expected in the next year compared to the current price of 47.02.
GPCR Groups
Sector & Classification
GPCR Financial Highlights
Over the last trailing twelve months GPCR reported a non-GAAP Earnings per Share(EPS) of -4.22. The EPS decreased by -75.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.91% | ||
| ROE | -9.31% | ||
| Debt/Equity | 0 |
GPCR Ownership
GPCR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.24 | 867.014B | ||
| JNJ | JOHNSON & JOHNSON | 18.18 | 555.546B | ||
| MRK | MERCK & CO. INC. | 22.51 | 283.098B | ||
| PFE | PFIZER INC | 8.92 | 151.709B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.32 | 120.503B | ||
| ZTS | ZOETIS INC | 16.41 | 48.806B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.61 | 28.639B | ||
| VTRS | VIATRIS INC | 5.91 | 17.175B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.28 | 11.181B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.346B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.169B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.097B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.08 | 4.795B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GPCR
Company Profile
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California and currently employs 220 full-time employees. The company went IPO on 2023-02-03. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. The company is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. The company is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Company Info
IPO: 2023-02-03
STRUCTURE THERAPEUTICS INC
601 Gateway Blvd Suite 900
South San Francisco CALIFORNIA US
Employees: 220
Phone: 16504571978
STRUCTURE THERAPEUTICS INC / GPCR FAQ
What does STRUCTURE THERAPEUTICS INC do?
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California and currently employs 220 full-time employees. The company went IPO on 2023-02-03. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. The company is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. The company is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
What is the stock price of STRUCTURE THERAPEUTICS INC today?
The current stock price of GPCR is 47.02 USD. The price increased by 1.12% in the last trading session.
What is the dividend status of STRUCTURE THERAPEUTICS INC?
GPCR does not pay a dividend.
What is the ChartMill rating of STRUCTURE THERAPEUTICS INC stock?
GPCR has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists GPCR stock?
GPCR stock is listed on the Nasdaq exchange.
What is STRUCTURE THERAPEUTICS INC worth?
STRUCTURE THERAPEUTICS INC (GPCR) has a market capitalization of 3.32B USD. This makes GPCR a Mid Cap stock.
Can you provide the upcoming earnings date for STRUCTURE THERAPEUTICS INC?
STRUCTURE THERAPEUTICS INC (GPCR) will report earnings on 2026-05-06, after the market close.